Anastrozole
Anastrozole is a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the aromatase enzyme responsible for converting androgens into oestrogens, thereby reducing circulating oestrogen levels and limiting the growth of hormone-sensitive cancer cells. Anastrozole is administered orally, usually once daily, and may be prescribed as adjuvant treatment for early breast cancer or for locally advanced or metastatic disease, depending on the clinical setting. Common adverse effects include hot flushes, joint pain, stiffness, fatigue, and headache. Long-term treatment may reduce bone mineral density and increase the risk of osteoporosis and fractures; changes in cholesterol levels may also occur. Treatment should be supervised by an oncologist, with appropriate monitoring of bone health, treatment response, and other relevant clinical parameters.
Anastrozole was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Anastrozole, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Anastrozole from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Anastrozole, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
